The trial will include 51 adult participants with Parkinson's disease and postural instability and gait disorders (PD-PIGD) and 20 age- and sex-matched healthy controls. At baseline (T0) patients will undergo neurological and cognitive/behavioural assessments, gait/balance evaluation, neuroimaging/neurophysiology assessments including brain magnetic resonance imaging (MRI), functional Near Infrared Spectroscopy (fNIRS) and Electroencephalography (EEG) acquisitions to assess brain activity, connectivity and structural changes, and blood sample. PD-PIGD patients will be randomly allocated in two training groups: the REHAB+SHAM group and the REHAB + STIM group. The REHAB+SHAM group will perform 2 cycles of dual-task gait/balance training consisting of action observation training (AOT) and motor imagery (MI) combined with practicing the observed-imagined exercises (an approach that has been demonstrated to be effective to improve gait and mobility in PD-PIGD), additionally they will undergo SHAM transcranial and trans-spinal stimulation. SHAM stimulation will be performed using the same montage used for transcranial and spinal stimulation (explained below), however an initial current is delivered and programmed to fade off in a brief period of time. The REHAB + STIM group will perform the same exercises combined with non-invasive stimulation. Non-invasive stimulation will be administered using tDCS with trans-spinal Direct Current Stimulation (tsDCS) or transcranial Direct Current Stimulation (tDCS) alone combined with SHAMtsDCS. This design will aid in determining not only whether non-invasive stimulation can enhance rehabilitation outcomes but also whether the combination of tDCS and tsDCS could lead to improved results compared to tDCS alone. The motor-cognitive training of the REHAB+SHAM group will consist of 2 cycles of SHAM stimulation and training lasting 6 weeks, 3 times per week, about 1 hour each session, separated by a 8-week washout period. The REHAB + STIM group will undergo 2 cycles of the 6-week training, separated by a 8-week washout period with a cross-over design: half of subjects will first receive 6-week training with tDCS+SHAMtsDCS followed by 6-week tDCS+ tsDCS, while the other half will follow the reverse order, according to a randomization procedure. After the training (i.e., 6-week visit \[W6\] and 20-week visit \[W20\]), PD-PIGD patients will be re-evaluated through neurological, cognitive/behavioural, gait/balance, neuroimaging/neurophysiology assessments and blood sample. These measures (except for MRI at 14-week \[W14\] visit) will be also repeated at W14 and 28-week follow-up visits to assess maintenance of results. 20 healthy controls will also be recruited and evaluated at baseline. They will undergo the same assessments administered to PD-PIGD patients at T0 (neurological, cognitive/behavioural assessments, gait/balance evaluation using gait analysis systems, neuroimaging/neurophysiology, blood sample).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Enrollment
71
Two cycles of dual-task gait/balance training consisting of action observation training (AOT) and motor imagery (MI) combined with practicing the observed-imagined exercises. Three 1-hour sessions per week for 6 weeks. Cycle repeated after 8-week washout period.
SHAM stimulation will be performed using the same montage used for transcranial and spinal stimulation, however an initial current is delivered and programmed to fade off in a brief period of time.
Anodic tDCS with the anode placed on the of the left DorsoLateral Prefrontal Cortex. Patients will undergo 30 minutes tDCS session preceding rehabilitation
Anodic spinal cervical stimulation with anode electrode placed on the spinous process of C3 vertebra and cathode placed on T3. Patients will undergo 30 minutes stimulation session preceding rehabilitation during the first cycle (6 weeks)
Anodic spinal cervical stimulation with anode electrode placed on the spinous process of C3 vertebra and cathode placed on T3. Patients will undergo 30 minutes stimulation session preceding rehabilitation during the second cycle (6 weeks after 8-week washout)
SHAM stimulation will have the same montage as tsDCS but run in SHAM more with an initial stimulation at standard intensity, followed by a programmed fade off after a brief time period. Patients will undergo 30 minutes of SHAM stimulation session preceding rehabilitation during the first cycle (6 weeks)
SHAM stimulation will have the same montage as tsDCS but run in SHAM more with an initial stimulation at standard intensity, followed by a programmed fade off after a brief time period. Patients will undergo 30 minutes of SHAM stimulation session preceding rehabilitation during the second cycle (6 weeks after 8-week washout)
SHAM stimulation will have the same montage as tsDCS but run in SHAM more with an initial stimulation at standard intensity, followed by a programmed fade off after a brief time period. Patients will undergo 30 minutes of SHAM stimulation session preceding rehabilitation
San Raffaele Neurotech Hub
Milan, Italy
RECRUITINGTotal execution time of Timed Up and Go test with cognitive dual-task (TUG-COG)
Changes in time taken to complete the timed up and go test with cognitive dual-task: patients are asked to stand up from a chair, walk for three meters, turn and walk back to the chair while counting backwards by 3 starting from 100. Assessment during ON medication phase
Time frame: Baseline, week 6, week 14, week 20 and week 28
Total execution time of Timed Up and Go test (TUG)
Changes in time taken to complete the timed up and go test: patients are asked to stand up from a chair, walk for three meters, turn, and walk back to the chair. Assessment during ON medication phase
Time frame: Baseline, week 6, week 14, week 20 and week 28
Total execution time of Timed Up and Go test with manual dual-task (TUG-MAN)
Changes in time taken to complete the timed up and go test with manual dual-task: patients are asked to stand up from a chair, walk for three meters, turn, and walk back to the chair while holding a glass full of water. Assessment during ON medication phase
Time frame: Baseline, week 6, week 14, week 20 and week 28
Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score
MDS-UPDRS evaluates various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications. The MDS-UPDRS contains 65 items divided in four parts (Part I - "non-motor experiences of daily living", Part II - "motor experiences of daily living", Part III - "motor examination", Part IV - "motor complications. Each item is assessed with a 0 to 4 rating system. The total score ranges from 0 to 260 with higher score indicating more severe symptoms. Assessment during ON medication. Only part III assessed also without medication (OFF).
Time frame: Baseline, week 6, week 14, week 20 and week 28
Brain functional changes during functional magnetic resonance imaging (MRI) tasks
Changes in functional MRI brain activity assessed during a motor task, a cognitive task and a dual-task. Assessment during OFF medication phase, at least 12 hours after last medication assumption.
Time frame: Baseline, week 6, week 20 and week 28
Changes at resting-state functional Near-Infrared Spectroscopy (fNIRS)
Changes in the continuous spectral wave of brain resting activity
Time frame: Baseline, week 6, week 14, week 20 and week 28
Changes in Electroencephalography (EEG) signal
Changes in electrical brain activity during resting with eyes open and eyes closed
Time frame: Baseline, week 6, week 14, week 20 and week 28
Serum concentration of Neurofilament light chain (NfL)
Serum biomarker of neuroprotection/neurodegeneration
Time frame: Baseline, week 6, week 14, week 20 and week 28
Activity Balance Confidence questionnaire (ABC) score
This questionnaire assesses patient-referred balance confidence during 16 daily tasks. Subjects rate their confidence while doing each activity from 0 (no confidence) to 100 (full confidence). Assessment during ON medication phase.
Time frame: Baseline, week 6, week 14, week 20 and week 28
10-meter walk test (10MWT) time
Time taken to walk 10 straight meters. Test performed at comfortable and maximal speed. Assessment during ON medication phase.
Time frame: Baseline, week 6, week 14, week 20 and week 28
Mini Balance Evaluation System Test (MiniBESTest) score
Assessment of different balance systems (anticipatory, reactive postural control, sensory orientation, dynamic gait). MiniBESTest includes 14 items with a score from 0 (severe/unable) to 2 (normal). The maximum score is 28 and a higher score indicates a better balance. Assessment during ON medication phase.
Time frame: Baseline, week 6, week 14, week 20 and week 28
Five-time sit-to-stand (5STS) time
This test measures the amount of time it takes for a patient to stand up and sit down five times in a row, as quickly as possible with arms folded across their chest. Assessment during ON medication phase.
Time frame: Baseline, week 6, week 14, week 20 and week 28
Parkinson's Disease Questionnaire (PDQ-39) score
Parkinson's Disease Questionnaire investigates the quality of life of PD patients. It includes 39 questions with 5 possible answers (never, occasionally, sometimes, often, always) and 8 sub-items related to mobility, activities of daily living, emotional well-being, signs of discouragement, social support, cognitions, communication and bodily discomfort. The maximum score is 100 and a low score is an indicator of a good quality of life. Assessment during ON medication phase.
Time frame: Baseline, week 6, week 14, week 20 and week 28
Kinesthetic and Visual Imagery Questionnaire (KVIQ)
This questionnaire assesses motor imagery abilities. The Kinesthetic and Visual Imagery Questionnaire (KVIQ) includes 10 items assessing the clarity of the image and the intensity of the sensations that the subject is able to imagine from the first-person perspective (both right and left sides) on a five-point ordinal scale. Total score ranges from 0 to 50 with higher score indicating better motor imagery abilities. Assessment during ON medication phase.
Time frame: Baseline, week 6, week 14, week 20 and week 28
Vividness of Movement imagery Questionnaire (VMIQ)
This questionnaire measures vividness of imagery in different visual imagery modalities (first and third person view) and kinaesthetic modality. Patients, for each imagery modality, give a score from 1 (best) to 5 (worse) to the clarity/intensity of 12 imagined actions.
Time frame: Baseline, week 6, week 14, week 20 and week 28
Parkinson Fatigue Scale (PFS)
Patient-rated scale that reflects the physical aspects of fatigue in patients with Parkinson's Disease (PD) and measures both the presence of fatigue and its impact on daily function
Time frame: Baseline, week 6, week 14, week 20 and week 28
Fatigue Severity Scale (FSS)
9-item scale which measures the severity of fatigue and its effect on a person\'s activities and lifestyle
Time frame: Baseline, week 6, week 14, week 20 and week 28
Modified Fatigue Impact Scale (M-FIS)
Provides an assessment of the effects of fatigue in terms of physical, cognitive, and psychosocial functioning
Time frame: Baseline, week 6, week 14, week 20 and week 28
New Freezing of Gait Questionnaire (NFoG-Q)
This is a self-reported questionnaire that measures freezing of gait. It consists of 9 items with a total score ranging from 0 (no freezing) to 28. Higher score indicates worse freezing. Assessment during ON medication phase.
Time frame: Baseline, week 6, week 14, week 20 and week 28
Stride length
Gait parameter obtained using wearable motion sensors. Assessment during ON medication phase.
Time frame: Baseline, week 6, week 14, week 20 and week 28
Gait velocity
Gait parameter obtained using wearable motion sensors. Assessment during ON medication phase.
Time frame: Baseline, week 6, week 14, week 20 and week 28
Cambridge Neuropsychological Test Automated Battery (CANTAB)
This battery of cognitive tests assesses executive functions, memory and visuospatial abilities. Each subtest of the CANTAB battery provides outcome measures in terms of accuracy (right answers, errors and/or missing answers) and reaction times (highest scores are worse) for every condition within the subtest (the different conditions present with different levels of cognitive load). Assessment during ON medication phase.
Time frame: Baseline, week 6, week 14, week 20 and week 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.